Welcome to our dedicated page for Kronos Bio news (Ticker: KRON), a resource for investors and traders seeking the latest updates and insights on Kronos Bio stock.
About Kronos Bio, Inc.
Kronos Bio, Inc. (Nasdaq: KRON) is a clinical-stage biopharmaceutical company dedicated to developing innovative small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription. Transcriptional dysregulation is a hallmark of many complex diseases, and Kronos Bio employs its proprietary discovery engine to decode transcription factor regulatory networks, identifying druggable cofactors that play critical roles in disease progression. By targeting these cofactors in a disease-specific context, the company aims to transform patient outcomes in areas of significant unmet medical need.
Proprietary Technology and Expertise
Kronos Bio's competitive edge lies in its proprietary discovery platform, which integrates high-throughput screening strategies and small molecule microarray (SMM) technology. This platform enables the company to identify and optimize small molecules that specifically target transcriptional drivers of disease. The focus on transcription factor regulatory networks allows Kronos Bio to address historically recalcitrant targets, opening new therapeutic possibilities in oncology and autoimmune diseases.
Pipeline and Therapeutic Focus
The company's pipeline includes multiple drug candidates at various stages of development:
- Istisociclib (KB-0742): A CDK9 inhibitor designed to address MYC deregulation in solid tumors, currently being evaluated in a Phase 1/2 clinical trial for platinum-resistant high-grade serous ovarian cancer.
- KB-9558: A p300 lysine acetyltransferase (KAT) inhibitor targeting IRF4 dependence in multiple myeloma and HPV-driven tumors, with preclinical data demonstrating potential tumor suppression through restoration of p53 and Rb pathways.
- KB-7898: Kronos Bio's first autoimmune development candidate, targeting Sjögren’s disease. This p300 KAT inhibitor modulates inflammatory signaling pathways and has shown preclinical efficacy in reducing inflammatory cytokines and antibody production.
By focusing on these disease-specific mechanisms, Kronos Bio aims to provide therapeutic solutions for patient populations with limited or no treatment options.
Market Position and Challenges
Operating within the highly competitive biopharmaceutical industry, Kronos Bio faces challenges such as the inherent risks of drug development, regulatory hurdles, and the need for substantial financial resources. However, its emphasis on transcriptional dysregulation as a therapeutic target sets it apart from competitors, offering a unique value proposition. The company's focus on oncology and autoimmune diseases—markets with high unmet medical needs—positions it as a key player in these segments.
Commitment to Innovation
Kronos Bio's mission is underpinned by a commitment to scientific excellence and innovation. By leveraging its advanced discovery engine and expertise in transcriptional biology, the company continues to push the boundaries of what is possible in drug discovery and development. Its efforts are directed toward creating first-in-class therapies that have the potential to significantly improve the lives of patients worldwide.
Kronos Bio (KRON) reported Q2 2024 financial results and pipeline updates. Key highlights include:
1. First patient dosed with istisociclib (KB-0742) in platinum-resistant high-grade serous ovarian cancer; data expected in 1H 2025.
2. KB-9558 IND-enabling studies for multiple myeloma on track for Q4 2024 completion.
3. New potential indication for KB-9558 in HPV-driven tumors announced.
4. New p300 program for autoimmune indications in development.
5. $136.6 million cash position expected to fund operations into 2H 2026.
6. Q2 2024 financial results: R&D expenses $13.8M, G&A expenses $6.4M, net loss $16.2M ($0.27 per share).
Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provide a 1.8-fold increase in AUC compared to the previous 60mg three-days-on, four-days-off schedule.
KB-0742 has shown a favorable safety profile in over 100 patients, with no grade 3 or 4 neutropenia observed. The company plans to provide an efficacy update on this expansion cohort in the first half of 2025. HGSOC is particularly sensitive to CDK9 inhibition due to MYC amplification or overexpression and homologous recombination deficiencies, affecting a significant portion of ovarian cancer patients.
Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, three-days-off cohort is currently enrolling, with an expansion cohort expected in Q3 2024. Data from 103 patients revealed manageable mild to moderate nausea and vomiting, and less than 10% discontinued due to adverse events. Anti-tumor activity was observed in case studies, and pharmacokinetic modeling predicts increased efficacy at the 80mg dose.
Kronos Bio announces its participation in three upcoming healthcare conferences. CEO Norbert Bischofberger will represent Kronos Bio at these events. On May 28, 2024, he will join a virtual fireside chat at TD Cowen's Oncology Innovation Summit. On June 5, 2024, he will present a corporate overview and host investor meetings at the Jefferies Global Healthcare Conference in New York. Lastly, on June 11, 2024, he will participate in a fireside chat and host investor meetings at the Goldman Sachs Global Healthcare Conference in Miami. Live webcasts of these events will be available on Kronos Bio's website.
Kronos Bio is a clinical-stage company focused on developing small molecule therapeutics for cancers driven by deregulated transcription. Its drug candidates include KB-0742, targeting CDK9 for solid tumors, and KB-9558, targeting p300 for multiple myeloma.
Kronos Bio announced the appointment of Deborah Knobelman, Ph.D., as Chief Operating Officer and Chief Financial Officer, effective June 3, 2024.
Dr. Knobelman brings extensive experience from her previous roles at Senti Bio, Jogo Health, Thinklabs, Aktiv Pharma Group, GeneriCo, and Ampio Pharmaceuticals.
She will oversee finance, accounting, business development, investor relations, and corporate strategy at Kronos Bio.
Dr. Knobelman's addition aims to strengthen the company's leadership as it advances its small molecule therapeutics for cancer and other diseases driven by deregulated transcription.
Kronos Bio's current pipeline includes two internally developed drug candidates, KB-0742 and KB-9558, targeting transcription factors in specific cancers.
Kronos Bio, Inc. (Nasdaq: KRON) reported strong financial results for the first quarter of 2024 with $152.0 million in cash, providing a cash runway into the second half of 2026. The company made progress on its clinical programs, with an update on KB-0742-1001 expected at ASCO. IND-enabling studies for KB-9558 are on track, with the first-in-human study set to begin in the first half of 2025. Kronos Bio also presented new data at the AACR Annual Meeting in April 2024, showcasing advancements in its p300 program and CDK9 inhibitor studies. Despite a net loss of $30.0 million for the quarter, the company remains focused on advancing its collaborations and internal discovery programs.